Recently, FTSE Russell (the trading name of FTSE International Limited and Frank Russell Company) confirms that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (referred to as Jiuzhou Pharma) has been independently assessed according to the FTSE4Good criteria, and has satisfied the requirements to become a constituent of the FTSE4Good Index Series. Created by the global index provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.

It is the first time that Jiuzhou Pharma included in the FTSE4Good Index Series, which demonstrates the capital market's full recognition of Jiuzhou Pharma ESG management capabilities.

As a member of the United Nations Global Compact, Jiuzhou Pharma will continue to uphold the mission of "serve life, guard health." With the vision of being a global outstanding life science company with innovative drug solutions, it will implement sustainable development principles to achieve harmonious coexistence among society, environment, and stakeholders. Additionally, Jiuzhou Pharma will actively explore and collaborate with partners to shape a sustainable future.

For more information on Jiuzhou Pharma's social, environmental, and governance initiatives, please refer to the Jiuzhou Pharmaceutical 2023 Sustainability and ESG Report (click the link to view).

Recently, FTSE Russell (the trading name of FTSE International Limited and Frank Russell Company) confirms that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (referred to as Jiuzhou Pharma) has been independently assessed according to the FTSE4Good criteria, and has satisfied the requirements to become a constituent of the FTSE4Good Index Series. Created by the global index provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.

It is the first time that Jiuzhou Pharma included in the FTSE4Good Index Series, which demonstrates the capital market's full recognition of Jiuzhou Pharma ESG management capabilities.

As a member of the United Nations Global Compact, Jiuzhou Pharma will continue to uphold the mission of "serve life, guard health." With the vision of being a global outstanding life science company with innovative drug solutions, it will implement sustainable development principles to achieve harmonious coexistence among society, environment, and stakeholders. Additionally, Jiuzhou Pharma will actively explore and collaborate with partners to shape a sustainable future.

For more information on Jiuzhou Pharma's social, environmental, and governance initiatives, please refer to the Jiuzhou Pharmaceutical 2023 Sustainability and ESG Report (click the link to view).

Recently, FTSE Russell (the trading name of FTSE International Limited and Frank Russell Company) confirms that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (referred to as Jiuzhou Pharma) has been independently assessed according to the FTSE4Good criteria, and has satisfied the requirements to become a constituent of the FTSE4Good Index Series. Created by the global index provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.

It is the first time that Jiuzhou Pharma included in the FTSE4Good Index Series, which demonstrates the capital market's full recognition of Jiuzhou Pharma ESG management capabilities.

As a member of the United Nations Global Compact, Jiuzhou Pharma will continue to uphold the mission of "serve life, guard health." With the vision of being a global outstanding life science company with innovative drug solutions, it will implement sustainable development principles to achieve harmonious coexistence among society, environment, and stakeholders. Additionally, Jiuzhou Pharma will actively explore and collaborate with partners to shape a sustainable future.

For more information on Jiuzhou Pharma's social, environmental, and governance initiatives, please refer to the Jiuzhou Pharmaceutical 2023 Sustainability and ESG Report (click the link to view).